Clinical Trial Update: Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the addition of radiation to HER2-targeted therapy versus HER2-targeted therapy alone for low-risk HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HER2-targeted therapy

Snippet

Sponsor: NRG Oncology | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING